A draft guideline by the United States Preventive Services Task Force recommends that colorectal cancer screening should begin five years earlier—at age 45 for average-risk individuals.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
